

Date: 30th May, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai - 400 001

Dear Sir / Ma'am,

**Sub: Submission of Audited Financial Results for the Quarter and Year on
31st March, 2022 along with Auditor's Report and Declaration
Ref: Security Id: EVOQ / Script Code: 543500**

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Audited Financial Results for the Quarter and Year ended on 31st March, 2022 along with Auditor's Report and Declaration.

Kindly take same on your record and oblige us.

Thanking You.

Yours Faithfully,

For, Evoq Remedies Limited

Bhumishth Patel
Managing Director
DIN: 02516641

EVOQ REMEDIES LTD. CIN:U24230GJ2010PLC059692

F-12,V R Complex ,Nr Sanathal Cross Road ,S P Ring Road ,Sanathal ,Ahmedabad-382210

BALANCE SHEET AS ON 31st MARCH 2022

Particulars	Note No.	Year Ended	
		31.03.2022	31.03.2021
		(Audited)	(Audited)
		Rs. (In Lacs)	Rs. (In Lacs)
I. EQUITY AND LIABILITIES			
1 Shareholders Funds			
(a) Share Capital	3	1,360.00	1.00
(b) Reserves and Surplus	4	956.63	73.30
(c) Money Received Against Share Warrants		-	-
2 Share Application Money Pending Allotment			-
3 Non-Current Liabilities			
(a) Long-Term Borrowings	5	-	-
(b) Deferred Tax Liabilities (Net)	6	-	0.12
(c) Other Long Term Liabilities			
(d) Long-Term Provisions		-	
4 Current Liabilities			
(a) Short-Term Borrowings	7	815.80	-
(b) Trade Payables	8	120.86	678.26
(c) Other Current Liabilities	9	43.14	20.24
(d) Short-Term Provisions	10	36.71	31.71
TOTAL >>>>		3,333.14	804.63
II. ASSETS			
Non-Current Assets			
1 (a) Fixed Assets			
(i) Tangible Assets			
(ii) Intangible Assets			
(iii) Capital Work-In-Progress			
(iv) Intangible Assets under Development			
(b) Non-Current Investments			
(c) Deferred Tax Assets (Net)			
(d) Long-Term Loans and Advances			
(e) Other Non-Current Assets			
2 Current Assets			
(a) Current Investments			
(b) Inventories	11	78.44	15.07
(c) Trade Receivables	12	2,539.75	683.61
(d) Cash and Cash Equivalents	13	309.42	3.33
(e) Short-Term Loans and Advances	14	373.51	87.00
(f) Other Current Assets	15	32.02	15.62
TOTAL >>>>		3,333.14	804.63
See accompanying notes forming part of the Financial Statements			

As per our report of even date

For, M/s. J M PATEL & BROS.,
FRN:107707W

Jashwant M Patel
CA JASHWANT M PATEL
(M. NO: 030161)

PLACE: AHMEDABAD
DATE: 30/05/2022



For, Evoq Remedies Limited

Brumishth Patel
BRUMISHTH PATEL
(Managing Director)
DIN -02516641

Payal Patel
PAYAL PATEL
(Whole Time Director)
DIN -05300011

Y.M. Rajput
YOGESH RAJPUT
(CFO)

UDIN NO.

22030161AJWKEF7051

EVOQ REMEDIES LTD. CIN:U24230GJ2010PLC059692

F-12,V R Complex ,Nr Sanathal Cross Road ,S P Ring Road ,Sanathal ,Ahmedabad-382210

PROFIT & LOSS ACCOUNT FOR THE TWELVE MONTH PERIOD ENDED ON 31ST March 2022


Particulars	Note No.	6 Months Ended			Year Ended	
		31.03.2022 (Audited)	30.09.2021 (Unaudited)	31.03.2021 (Audited)	For the Period Ended 31st March 2022	For the Period Ended 31st March 2021
		Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)
I. Revenue from Operations	16	1185.04	493.27	275.96	1,678.31	1,002.48
II Other Income	17	0.00	0.00	0.00	-	-
Total Revenue (I + II)		1,185.04	493.27	275.96	1,678.31	1,002.48
III. Expenses:						
Purchases of material	18	1033.26	407.57	68.11	1,440.83	794.33
Changes in Inventories	19	(59.41)	(3.97)	(7.96)	(63.38)	(9.01)
Employee Benefits Expenses	20	13.20	4.1	0.00	17.30	1.17
Finance Costs	21	0.46	0	0.00	0.46	0.02
Depreciation and Amortization expense		0.00	0	0.00	-	-
Other Expenses	22	124.80	12.46	111.24	137.26	120.57
Total Expenses		1,112.31	420.16	171.39	1,532.47	907.08
IV. Profit before exceptional and extraordinary items and tax (III-IV)		72.73	73.11	104.57	145.84	95.40
V. Exceptional Items						
Prior Period Expenses						
VI. Profit Before Extraordinary Items and Tax (V - VI)		72.73	73.11	104.57	145.84	95.40
VIII. Extraordinary Items						
IX. Profit before tax (VII- VIII)		72.73	73.11	104.57	145.84	95.40
X Tax expense:						
(1) Current tax		36.71	0	23.85	36.71	23.85
(2) Deferred tax						
XI Profit (Loss) for the period from continuing operations (VII-VIII)		36.02	73.11	80.72	109.13	71.55
XII Profit/(loss) from discontinuing operations						
XIII Tax expense of discontinuing operations						
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)						
XV Profit (Loss) for the period (XI + XIV)		36.02	73.11	80.72	109.13	71.55
XVI BALANCE BROUGHT FROM PREVIOUS YEAR						
XVII BALANCE CARRIED TO BALANCE SHEET		36.02	73.11	80.72	109.13	71.55
XVIII Earnings per equity share:						
(1) Basic		0.19	73.11	80.72	0.70	71.55
(2) Diluted		0.19	73.11	80.72	0.70	71.55

As per our report of even date

For, M/s. J M PATEL & BROS.,
FRN:107707W

Jashwant M Patel
CA JASHWANT M PATEL
(M. NO: 030161)

PLACE: AHMEDABAD
DATE: 30/05/2022



For, Evoq Remedies Limited
Ahmedabad
Bhumishth Patel
BHUMISHTH PATEL
(Managing Director)
DIN -02516641
Payal Patel
PAYAL PATEL
(Whole Time Director)
DIN-05300011

Yogesh Rajput
YOGESH RAJPUT
(CFO)

UDIN NO.


22030161AJWKEF7051

CASH FLOW STATEMENT



(Rs. In Lacs)

	For the Period Ended 31st March 2022	For the Year Ended 31st March,2021
Cash flows from operating activities		
Profit before taxation	145.84	95.40
Adjustments for:		
Depreciation	-	-
Investment income	-	-
Deferred tax Liability	-	-
Interest expense	0.46	0.02
Profit / (Loss) on the sale of property, plant & equipment	-	-
Working capital changes:		
(Increase) / Decrease in trade and other receivables	(1,856.14)	(211.82)
(Increase) / Decrease in inventories	(63.37)	(9.01)
(Increase) / Decrease in Short Term Loan & Advance	(286.51)	-
(Increase) / Decrease in Other Current Assets	(16.40)	(15.48)
Increase / (Decrease) in Trade payables	(557.40)	115.92
Increase / (Decrease) in Short term Provisions	5.00	31.72
Increase / (Decrease) in Other Current Liabilities	22.78	20.24
Cash generated from operations	(2,605.74)	26.99
Interest paid	(0.46)	(0.02)
Income taxes paid	(36.71)	(23.85)
Dividends paid	-	-
Net cash from operating activities	(2,642.91)	3.12
Cash flows from investing activities		
Business acquisitions, net of cash acquired	-	-
Purchase of property, plant and equipment	-	-
Proceeds from sale of equipment	-	-
Acquisition of portfolio investments	-	-
Investment income	-	-
Net cash used in investing activities	-	-
Cash flows from financing activities		
Proceeds from issue of share capital	1,289.00	-
Proceeds from long-term borrowings	-	-
Proceeds from Short-term borrowings	815.80	-
Payment of Share Application Money	-	-
Share Capital Issue With Security Premium	844.20	-
Net cash used in financing activities	2,949.00	-
Net increase in cash and cash equivalents	306.09	3.11
Cash and cash equivalents at beginning of period	3.33	0.22
Cash and cash equivalents at end of period	309.42	3.33


As per our report of even date

For, M/s. J M PATEL & BROS.,
FRN:107707W

 CA JASHWANT M PATEL
 (M. NO: 030161)
PLACE: AHMEDABAD
DATE: 30/05/2022

For, EVOQ Remedies Limited

BHJIMETH PATEL (Managing Director) DIN -02516641
 PAVAL PATEL (Whole Time Director) DIN -05300011


 YOGESH RAJPUT
 (CFO)

UDIN NO.

22030161AJWKEF7051

J. M. PATEL & BROS.

CHARTERED ACCOUNTANTS

E-mail : jmpatelca@yahoo.co.in

204, Harsh Avenue,
Navjivan Press Road,
Nr. Old High Court Crossing,
AHMEDABAD - 380 014.
Phone: (079) 27541460

Ref. No. :

Date :

Independent Auditor's Report (Unmodified Opinion) on Audited Standalone Half Yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF
EVOQ REMEDIES LIMITED

Report on the audit of the Standalone Financial Results

Opinion


We have audited the accompanying standalone half yearly financial results of **Evoq Remedies Limited** (the company) for the half year ended 31st March, 2022 and the year to date results for the period from 1st April, 2021 to 31st March, 2022, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the half year ended 31st March, 2022 as well as the year to date results for the period from 1st April, 2021 to 31st March, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

These half yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the accounting principles generally accepted in India including Accounting Standard prescribed under Section 133 of the Companies Act, 2013 , read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for



our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Place: Ahmedabad
Date: 30/05/2022

FOR, J M PATEL & BROS.,
CHARTERED ACCOUNTANTS
FIRM REGISTRATION NO.: 107707W


CA JASHWANT M. PATEL
M. NO.: 030161
UDIN:

UDIN NO.

2	2	0	3	0	1	6	1	A	J	W	K	E	F	7	0	5	1
---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

Date: 30th May, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai - 400 001

Dear Sir / Ma'am,

Sub: Declaration in respect of Unmodified Opinion on Audited Financial Result for the Financial Year ended on 31st March, 2022
Ref: Security Id: EVOQ / Script Code: 543500

We hereby declared that the Statutory Auditor of the Company, M/s. J. M. Patel & Bros., Chartered Accountants, Ahmedabad has issued Audit Report with Unmodified Opinion on Audited Financial Result for the Quarter and Financial Year ended as on 31st March, 2022.

The declaration is given in compliance to second proviso of Reg. 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment), Regulations 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001, dated 25th May, 2016.

Kindly take same on your record and oblige us.

Thanking You.

For, Evoq Remedies Limited

Bhumishth Patel
Managing Director
DIN: 02516641